These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26686252)

  • 21. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.
    Kurstin R
    Oncology (Williston Park); 2002 Jan; 16(1):21-4. PubMed ID: 11831608
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Poetker DM; Choong NW
    N Engl J Med; 2011 Feb; 364(7):688-9. PubMed ID: 21323562
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thalidomide: new therapeutic indications?].
    Nau JY
    Rev Med Suisse; 2010 Apr; 6(245):846-7. PubMed ID: 20469670
    [No Abstract]   [Full Text] [Related]  

  • 25. Evidence-based management of epistaxis in hereditary haemorrhagic telangiectasia.
    Syed I; Sunkaraneni VS
    J Laryngol Otol; 2015 May; 129(5):410-5. PubMed ID: 25736077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
    Gaillard S; Dupuis-Girod S; Boutitie F; Rivière S; Morinière S; Hatron PY; Manfredi G; Kaminsky P; Capitaine AL; Roy P; Gueyffier F; Plauchu H;
    J Thromb Haemost; 2014 Sep; 12(9):1494-502. PubMed ID: 25040799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A natural obturator in hereditary haemorrhagic telangiectasia.
    Soni-Jaiswal A; Woolford TJ
    J Laryngol Otol; 2009 Jun; 123(6):695-6. PubMed ID: 19275781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia.
    Richtsmeier W; Weaver G; Streck W; Jacobson H; Dewell R; Olson J
    Otolaryngol Head Neck Surg; 1984 Oct; 92(5):564-70. PubMed ID: 6438587
    [No Abstract]   [Full Text] [Related]  

  • 30. Epistaxis--topical use of epsilon-aminocaproic acid in its management.
    Jash DK
    J Laryngol Otol; 1973 Sep; 87(9):895-8. PubMed ID: 4728302
    [No Abstract]   [Full Text] [Related]  

  • 31. Endoscopic-guided coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia: "How I do it".
    Poetker DM
    Am J Rhinol Allergy; 2017 May; 31(3):205-206. PubMed ID: 28490409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.
    Contis A; Gensous N; Viallard JF; Goizet C; Léauté-Labrèze C; Duffau P
    Clin Otolaryngol; 2017 Aug; 42(4):911-917. PubMed ID: 28032956
    [No Abstract]   [Full Text] [Related]  

  • 33. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.
    Yaniv E; Preis M; Hadar T; Shvero J; Haddad M
    Laryngoscope; 2009 Feb; 119(2):284-8. PubMed ID: 19160429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
    Chin CJ
    Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042
    [No Abstract]   [Full Text] [Related]  

  • 35. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series.
    Joshi H; Woodworth BA; Carney AS
    J Laryngol Otol; 2011 Nov; 125(11):1176-80. PubMed ID: 21846415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary haemorrhagic telangiectasia: the use of H2 receptor antagonist in symptomatic gastric telangiectasia.
    Kueh YK; LaBrooy S
    Ann Acad Med Singap; 1985 Oct; 14(4):682-5. PubMed ID: 2867733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
    Bowcock SJ; Patrick HE
    Br J Haematol; 2009 Jul; 146(2):220-2. PubMed ID: 19438503
    [No Abstract]   [Full Text] [Related]  

  • 38. Hereditary haemorrhagic telangiectasia.
    Mehta BC; Agarwal MB; Gupte SM
    J Indian Med Assoc; 1979 Apr; 72(8):190-1. PubMed ID: 521662
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
    Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
    Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.